BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dai Q, Ye Y. Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer. Front Cell Dev Biol 2022;10:793425. [DOI: 10.3389/fcell.2022.793425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Guo F, Wang H. Potential of histone deacetylase inhibitors for the therapy of ovarian cancer. Front Oncol 2022;12:1057186. [PMID: 36505774 DOI: 10.3389/fonc.2022.1057186] [Reference Citation Analysis]
2 Jia L, Gao Z, Chen J. High levels of m6A methylation and histone acetylation modification patterns contribute to the survival of LUAD patients.. [DOI: 10.21203/rs.3.rs-2199422/v1] [Reference Citation Analysis]
3 Hu X, Zhang X, Li S, Hua T. Construction and validation of a histone acetylation-related lncRNA prognosis signature for ovarian cancer. Front Genet 2022;13:934246. [DOI: 10.3389/fgene.2022.934246] [Reference Citation Analysis]
4 Zhao Y, Zhang Y, Dai C, Hong K, Guo Y. A signature constructed with mitophagy-related genes to predict the prognosis and therapy response for breast cancer. Aging. [DOI: 10.18632/aging.204209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]